Product Liability Litigation: 'Stand And Fight' Strategy Pays Off For Drug And Device Makers
Executive Summary
Legal analytics company Lex Machina finds that manufacturers most often win at summary judgement stage; however, about 96% of cases settle or are resolved procedurally.
You may also be interested in...
Product Liability Litigation Playbook: Pros And Cons For Pharma
Drug makers are winning cases by getting expert testimony tossed, but the AndroGel verdict shows how narrow claims can benefit plaintiffs. The Pink Sheet offers a look at drugs in multidistrict litigation from Abilify to Zoloft.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.
Current Pathways For Rare Disease Drugs Are Not Optimal, US FDA’s Califf Says
Anticipating a ‘tsunami of therapies’ for rare diseases, commissioner says the agency will have to think of creative approaches and employ regulatory flexibility for them. FDA considers copying the oncology center’s Project Facilitate for expanded access to other diseases.